The hitmaker, 50, was a guest on the show to promote his biopic Better Man, and during the interview, discussed the appearance of Jonno Davies, who plays his younger self.
The weight-loss market began feeling some growing pains as the year ended, creating more wariness for the upcoming year. For 2025, competition and supply constraints are areas to watch.
A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...
We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...
Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.
As weight-loss drugs have exploded in popularity this past year, part of the craze has been members of the public wondering which celebrities are on Ozempic.
The Nordic region accounts for about 1% of the world’s GDP and 0.3% of its population. Yet it has produced an impressive list ...
Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...